Akihiro Onishi

TL;DR: The future prospects are excellent for new heparins and new he parin-based therapeutics with improved properties, including unfractionated heparin, low molecular weight he parins and ultra-low molecular weightHeparins.

TL;DR: An improved understanding of heparin’s structure–activity relationships would offer potential for new therapeutic development through the engineering of polysaccharides through the amalgamation of several different disciplines, including carbohydrate synthesis, applied enzymology, metabolic engineering, and process biochemistry.

TL;DR: Three heparins from porcine, ovine, and bovine were characterized through state-of-the-art carbohydrate analysis methods with a view profiling their physicochemical properties and some insight is provided into the variability of heparin obtained from these three species.

TL;DR: Liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy analysis confirms an abundance of heparin's characteristic trisulfated disaccharide, as well as 3-O-sulfo containing residues critical for hepar in binding to antithrombin III and its anticoagulant activity.

TL;DR: Bovine heparins prepared from both intestines and lung are examined and compared to porcine intestinal heparin to establish the structural and functional similarities and potential differences between bovine and porcines he parins.